Focal Deletions of a Promoter Tether Activate the IRX3 Oncogene in T-Cell Acute Lymphoblastic Leukemia

Medicine, Hematology, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology, Genetics,
T-cell acute lymphoblastic leukemia   FTO gene   IRX3 oncogene   enhancer hijacking   CTCF binding site   noncoding genome   tumor suppressor mechanism  

Stage-specific Chromosomal Deletions Activate the IRX3 Oncogene in T-cell Acute Lymphoblastic Leukemia In the field of cancer research, understanding regulatory mechanisms of the noncoding genome remains a key focus, especially concerning how oncogenes can be aberrantly activated through non-canonical regulatory pathways. This paper, authored by Su...

Bleeding Events in Patients with Cancer: Incidence, Risk Factors, and Impact on Prognosis in a Prospective Cohort Study

Medicine, Hematology, Oncology,
cancer   bleeding events   risk factors   prognosis   prospective study   anticoagulation   mortality  

The Incidence, Risk Factors, and Prognostic Impact of Bleeding Risk in Cancer Patients: A Review of the Vienna Cancer, Thrombosis, and Bleeding Study Academic Background and Research Motivation Cancer patients frequently experience hemostatic dysregulation, yet existing research has primarily focused on cancer-associated venous thromboembolism (VTE...

Selective Targeting of Mutated Calreticulin by the Monoclonal Antibody INCA033989 Inhibits Oncogenic Function of MPN

Medicine, Hematology, Oncology, Life Sciences, Immunology,
mutated calreticulin   monoclonal antibody   myeloproliferative neoplasms   targeted therapy   oncogenic function   INCA033989   hematopoiesis  

Report on the Academic Paper on the Monoclonal Antibody INCA033989 for Targeting Mutated Calreticulin in Myeloid Tumors Background: Calreticulin Mutation-Driven Myeloproliferative Neoplasms Myeloproliferative neoplasms (MPNs) are hematological malignancies caused by somatic mutations occurring in multipotent hematopoietic stem cells (HSCs). These m...

Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute Lymphoblastic Leukemia: A COG-AALL03N1 Report

Medicine, Pediatrics, Hematology, Oncology,
Acute Lymphoblastic Leukemia   Antimetabolite   Dose Intensity   Children   Toxicity   Relapse Risk   Treatment Adherence  

Review of the Study on Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) Background and Research Question Acute Lymphoblastic Leukemia (ALL) is the most common form of leukemia in children. Current treatment strategies include risk-based induction therapy, response-adapted post-induction therapy,...

Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients with AML Treated with Venetoclax and Azacitidine

Medicine, Hematology, Oncology,
Acute Myeloid Leukemia   Venetoclax   Azacitidine   Genetic Risk Stratification   Prognostic Model   TP53 Mutation   FLT3-ITD Mutation  

Genetic Risk Stratification and Outcomes Among Treatment-Naive AML Patients Treated with Venetoclax and Azacitidine Academic Background Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, with prognosis closely related to the genetic characteristics of patients. The European LeukemiaNet (ELN) 2017 and 2022 risk stratifica...

Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: The DELPHINUS Study

Medicine, Pediatrics, Hematology, Oncology, Life Sciences, Immunology,
Daratumumab   Acute Lymphoblastic Leukemia   Lymphoblastic Lymphoma   Pediatric   Relapsed/Refractory   DELPHINUS Study   Chemotherapy  

Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: The DELPHINUS Study Academic Background Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) are among the most common malignancies in children. Although the cure rate for newly diagnosed ALL and LL patients is relatively high, 10% to ...